Adaptive Biotechnologies Corporation (NASDAQ: ADPT) Stock Competitors & Peer Comparison
See ADPT's competitors and their performance on the NASDAQ and across the wider stock market.
Peer Comparison Table: Biotechnology Industry
Detailed financial metrics including price, market cap, P/E ratio, and more for ADPT and its NASDAQ peers.
| Symbol | Price | Change % | Market Cap | P/E Ratio | EPS | Dividend Yield |
|---|---|---|---|---|---|---|
| ADPT | $22.92 | +3.71% | 3.7B | -42.44 | -$0.54 | N/A |
| VRTX | $485.65 | -0.08% | 123.3B | 25.80 | $18.82 | N/A |
| VRNA | $106.91 | +0.11% | 72.7B | -102.80 | -$1.04 | N/A |
| REGN | $676.69 | -0.33% | 69.7B | 14.83 | $45.63 | +0.54% |
| ARGX | $860.55 | +0.30% | 53.8B | 77.67 | $11.08 | N/A |
| SGEN | $228.74 | -0.07% | 43.2B | -57.19 | -$4.00 | N/A |
| RVMDW | $9.28 | +10.28% | 42B | -2.24 | -$4.15 | N/A |
| RVMD | $186.16 | +3.90% | 39.6B | -26.33 | -$7.07 | N/A |
| ALNY | $267.47 | -5.54% | 35.7B | 48.19 | $5.55 | N/A |
| ONC | $312.02 | -1.70% | 33.3B | 69.80 | $4.47 | N/A |
Stock Comparison
Vertex Pharmaceuticals Incorporated (NASDAQ: VRTX)
ADPT vs VRTX Comparison July 2026
Adaptive Biotechnologies Corporation (NASDAQ: ADPT) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ADPT stands at 3.7B. In comparison, VRTX has a market cap of 123.3B. Regarding current trading prices, ADPT is priced at $22.92 on the NASDAQ, while VRTX trades at $485.65.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ADPT currently has a P/E ratio of -42.44, whereas VRTX's P/E ratio is 25.80. In terms of profitability, ADPT's ROE is -0.24%, compared to VRTX's ROE of +0.24%. Regarding short-term risk, ADPT is more volatile compared to VRTX. This indicates higher risk in terms of short-term price fluctuations for ADPT.Check VRTX's competition here
Verona Pharma plc (NASDAQ: VRNA)
ADPT vs VRNA Comparison July 2026
Adaptive Biotechnologies Corporation (NASDAQ: ADPT) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ADPT stands at 3.7B. In comparison, VRNA has a market cap of 72.7B. Regarding current trading prices, ADPT is priced at $22.92 on the NASDAQ, while VRNA trades at $106.91.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ADPT currently has a P/E ratio of -42.44, whereas VRNA's P/E ratio is -102.80. In terms of profitability, ADPT's ROE is -0.24%, compared to VRNA's ROE of -0.02%. Regarding short-term risk, ADPT is more volatile compared to VRNA. This indicates higher risk in terms of short-term price fluctuations for ADPT.Check VRNA's competition here
Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN)
ADPT vs REGN Comparison July 2026
Adaptive Biotechnologies Corporation (NASDAQ: ADPT) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ADPT stands at 3.7B. In comparison, REGN has a market cap of 69.7B. Regarding current trading prices, ADPT is priced at $22.92 on the NASDAQ, while REGN trades at $676.69.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ADPT currently has a P/E ratio of -42.44, whereas REGN's P/E ratio is 14.83. In terms of profitability, ADPT's ROE is -0.24%, compared to REGN's ROE of +0.14%. Regarding short-term risk, ADPT is more volatile compared to REGN. This indicates higher risk in terms of short-term price fluctuations for ADPT.Check REGN's competition here
argenx SE (NASDAQ: ARGX)
ADPT vs ARGX Comparison July 2026
Adaptive Biotechnologies Corporation (NASDAQ: ADPT) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ADPT stands at 3.7B. In comparison, ARGX has a market cap of 53.8B. Regarding current trading prices, ADPT is priced at $22.92 on the NASDAQ, while ARGX trades at $860.55.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ADPT currently has a P/E ratio of -42.44, whereas ARGX's P/E ratio is 77.67. In terms of profitability, ADPT's ROE is -0.24%, compared to ARGX's ROE of +0.22%. Regarding short-term risk, ADPT is more volatile compared to ARGX. This indicates higher risk in terms of short-term price fluctuations for ADPT.Check ARGX's competition here
Seagen Inc. (NASDAQ: SGEN)
ADPT vs SGEN Comparison July 2026
Adaptive Biotechnologies Corporation (NASDAQ: ADPT) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ADPT stands at 3.7B. In comparison, SGEN has a market cap of 43.2B. Regarding current trading prices, ADPT is priced at $22.92 on the NASDAQ, while SGEN trades at $228.74.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ADPT currently has a P/E ratio of -42.44, whereas SGEN's P/E ratio is -57.19. In terms of profitability, ADPT's ROE is -0.24%, compared to SGEN's ROE of -0.21%. Regarding short-term risk, ADPT is more volatile compared to SGEN. This indicates higher risk in terms of short-term price fluctuations for ADPT.Check SGEN's competition here
Revolution Medicines, Inc. Warrant (NASDAQ: RVMDW)
ADPT vs RVMDW Comparison July 2026
Adaptive Biotechnologies Corporation (NASDAQ: ADPT) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ADPT stands at 3.7B. In comparison, RVMDW has a market cap of 42B. Regarding current trading prices, ADPT is priced at $22.92 on the NASDAQ, while RVMDW trades at $9.28.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ADPT currently has a P/E ratio of -42.44, whereas RVMDW's P/E ratio is -2.24. In terms of profitability, ADPT's ROE is -0.24%, compared to RVMDW's ROE of -0.83%. Regarding short-term risk, ADPT is less volatile compared to RVMDW. This indicates lower risk in terms of short-term price fluctuations for ADPT.Check RVMDW's competition here
Revolution Medicines, Inc. (NASDAQ: RVMD)
ADPT vs RVMD Comparison July 2026
Adaptive Biotechnologies Corporation (NASDAQ: ADPT) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ADPT stands at 3.7B. In comparison, RVMD has a market cap of 39.6B. Regarding current trading prices, ADPT is priced at $22.92 on the NASDAQ, while RVMD trades at $186.16.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ADPT currently has a P/E ratio of -42.44, whereas RVMD's P/E ratio is -26.33. In terms of profitability, ADPT's ROE is -0.24%, compared to RVMD's ROE of -0.83%. Regarding short-term risk, ADPT is more volatile compared to RVMD. This indicates higher risk in terms of short-term price fluctuations for ADPT.Check RVMD's competition here
Alnylam Pharmaceuticals, Inc. (NASDAQ: ALNY)
ADPT vs ALNY Comparison July 2026
Adaptive Biotechnologies Corporation (NASDAQ: ADPT) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ADPT stands at 3.7B. In comparison, ALNY has a market cap of 35.7B. Regarding current trading prices, ADPT is priced at $22.92 on the NASDAQ, while ALNY trades at $267.47.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ADPT currently has a P/E ratio of -42.44, whereas ALNY's P/E ratio is 48.19. In terms of profitability, ADPT's ROE is -0.24%, compared to ALNY's ROE of +0.98%. Regarding short-term risk, ADPT is more volatile compared to ALNY. This indicates higher risk in terms of short-term price fluctuations for ADPT.Check ALNY's competition here
BeOne Medicines AG (NASDAQ: ONC)
ADPT vs ONC Comparison July 2026
Adaptive Biotechnologies Corporation (NASDAQ: ADPT) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ADPT stands at 3.7B. In comparison, ONC has a market cap of 33.3B. Regarding current trading prices, ADPT is priced at $22.92 on the NASDAQ, while ONC trades at $312.02.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ADPT currently has a P/E ratio of -42.44, whereas ONC's P/E ratio is 69.80. In terms of profitability, ADPT's ROE is -0.24%, compared to ONC's ROE of +0.12%. Regarding short-term risk, ADPT is more volatile compared to ONC. This indicates higher risk in terms of short-term price fluctuations for ADPT.Check ONC's competition here
Roivant Sciences Ltd. (NASDAQ: ROIV)
ADPT vs ROIV Comparison July 2026
Adaptive Biotechnologies Corporation (NASDAQ: ADPT) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ADPT stands at 3.7B. In comparison, ROIV has a market cap of 24.8B. Regarding current trading prices, ADPT is priced at $22.92 on the NASDAQ, while ROIV trades at $34.51.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ADPT currently has a P/E ratio of -42.44, whereas ROIV's P/E ratio is -35.47. In terms of profitability, ADPT's ROE is -0.24%, compared to ROIV's ROE of -0.07%. Regarding short-term risk, ADPT is more volatile compared to ROIV. This indicates higher risk in terms of short-term price fluctuations for ADPT.Check ROIV's competition here
Moderna, Inc. (NASDAQ: MRNA)
ADPT vs MRNA Comparison July 2026
Adaptive Biotechnologies Corporation (NASDAQ: ADPT) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ADPT stands at 3.7B. In comparison, MRNA has a market cap of 24.5B. Regarding current trading prices, ADPT is priced at $22.92 on the NASDAQ, while MRNA trades at $61.82.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ADPT currently has a P/E ratio of -42.44, whereas MRNA's P/E ratio is -7.59. In terms of profitability, ADPT's ROE is -0.24%, compared to MRNA's ROE of -0.37%. Regarding short-term risk, ADPT is more volatile compared to MRNA. This indicates higher risk in terms of short-term price fluctuations for ADPT.Check MRNA's competition here
Incyte Corporation (NASDAQ: INCY)
ADPT vs INCY Comparison July 2026
Adaptive Biotechnologies Corporation (NASDAQ: ADPT) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ADPT stands at 3.7B. In comparison, INCY has a market cap of 23.3B. Regarding current trading prices, ADPT is priced at $22.92 on the NASDAQ, while INCY trades at $117.25.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ADPT currently has a P/E ratio of -42.44, whereas INCY's P/E ratio is 15.68. In terms of profitability, ADPT's ROE is -0.24%, compared to INCY's ROE of +0.29%. Regarding short-term risk, ADPT is more volatile compared to INCY. This indicates higher risk in terms of short-term price fluctuations for ADPT.Check INCY's competition here
Insmed Incorporated (NASDAQ: INSM)
ADPT vs INSM Comparison July 2026
Adaptive Biotechnologies Corporation (NASDAQ: ADPT) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ADPT stands at 3.7B. In comparison, INSM has a market cap of 23.3B. Regarding current trading prices, ADPT is priced at $22.92 on the NASDAQ, while INSM trades at $108.32.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ADPT currently has a P/E ratio of -42.44, whereas INSM's P/E ratio is -18.69. In terms of profitability, ADPT's ROE is -0.24%, compared to INSM's ROE of -1.30%. Regarding short-term risk, ADPT is more volatile compared to INSM. This indicates higher risk in terms of short-term price fluctuations for ADPT.Check INSM's competition here
BioNTech SE (NASDAQ: BNTX)
ADPT vs BNTX Comparison July 2026
Adaptive Biotechnologies Corporation (NASDAQ: ADPT) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ADPT stands at 3.7B. In comparison, BNTX has a market cap of 23.1B. Regarding current trading prices, ADPT is priced at $22.92 on the NASDAQ, while BNTX trades at $91.48.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ADPT currently has a P/E ratio of -42.44, whereas BNTX's P/E ratio is -19.80. In terms of profitability, ADPT's ROE is -0.24%, compared to BNTX's ROE of -0.07%. Regarding short-term risk, ADPT is more volatile compared to BNTX. This indicates higher risk in terms of short-term price fluctuations for ADPT.Check BNTX's competition here
United Therapeutics Corporation (NASDAQ: UTHR)
ADPT vs UTHR Comparison July 2026
Adaptive Biotechnologies Corporation (NASDAQ: ADPT) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ADPT stands at 3.7B. In comparison, UTHR has a market cap of 22.7B. Regarding current trading prices, ADPT is priced at $22.92 on the NASDAQ, while UTHR trades at $535.67.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ADPT currently has a P/E ratio of -42.44, whereas UTHR's P/E ratio is 19.77. In terms of profitability, ADPT's ROE is -0.24%, compared to UTHR's ROE of +0.19%. Regarding short-term risk, ADPT is more volatile compared to UTHR. This indicates higher risk in terms of short-term price fluctuations for ADPT.Check UTHR's competition here
BeiGene, Ltd. (NASDAQ: BGNE)
ADPT vs BGNE Comparison July 2026
Adaptive Biotechnologies Corporation (NASDAQ: ADPT) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ADPT stands at 3.7B. In comparison, BGNE has a market cap of 20.2B. Regarding current trading prices, ADPT is priced at $22.92 on the NASDAQ, while BGNE trades at $184.71.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ADPT currently has a P/E ratio of -42.44, whereas BGNE's P/E ratio is -22.55. In terms of profitability, ADPT's ROE is -0.24%, compared to BGNE's ROE of +0.12%. Regarding short-term risk, ADPT is more volatile compared to BGNE. This indicates higher risk in terms of short-term price fluctuations for ADPT.Check BGNE's competition here
Ginkgo Bioworks Holdings, Inc. WT (NYSE: DNA-WT)
ADPT vs DNA-WT Comparison July 2026
Adaptive Biotechnologies Corporation (NASDAQ: ADPT) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ADPT stands at 3.7B. In comparison, DNA-WT has a market cap of 18.7B. Regarding current trading prices, ADPT is priced at $22.92 on the NASDAQ, while DNA-WT trades at $0.27.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ADPT currently has a P/E ratio of -42.44, whereas DNA-WT's P/E ratio is N/A. In terms of profitability, ADPT's ROE is -0.24%, compared to DNA-WT's ROE of -0.57%. Regarding short-term risk, ADPT is more volatile compared to DNA-WT. This indicates higher risk in terms of short-term price fluctuations for ADPT.Check DNA-WT's competition here
Genmab A/S (NASDAQ: GMAB)
ADPT vs GMAB Comparison July 2026
Adaptive Biotechnologies Corporation (NASDAQ: ADPT) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ADPT stands at 3.7B. In comparison, GMAB has a market cap of 17.6B. Regarding current trading prices, ADPT is priced at $22.92 on the NASDAQ, while GMAB trades at $28.72.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ADPT currently has a P/E ratio of -42.44, whereas GMAB's P/E ratio is 20.66. In terms of profitability, ADPT's ROE is -0.24%, compared to GMAB's ROE of +0.15%. Regarding short-term risk, ADPT is more volatile compared to GMAB. This indicates higher risk in terms of short-term price fluctuations for ADPT.Check GMAB's competition here
Neurocrine Biosciences, Inc. (NASDAQ: NBIX)
ADPT vs NBIX Comparison July 2026
Adaptive Biotechnologies Corporation (NASDAQ: ADPT) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ADPT stands at 3.7B. In comparison, NBIX has a market cap of 17.2B. Regarding current trading prices, ADPT is priced at $22.92 on the NASDAQ, while NBIX trades at $170.88.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ADPT currently has a P/E ratio of -42.44, whereas NBIX's P/E ratio is 24.69. In terms of profitability, ADPT's ROE is -0.24%, compared to NBIX's ROE of +0.22%. Regarding short-term risk, ADPT is more volatile compared to NBIX. This indicates higher risk in terms of short-term price fluctuations for ADPT.Check NBIX's competition here
Ascendis Pharma A/S (NASDAQ: ASND)
ADPT vs ASND Comparison July 2026
Adaptive Biotechnologies Corporation (NASDAQ: ADPT) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ADPT stands at 3.7B. In comparison, ASND has a market cap of 16.2B. Regarding current trading prices, ADPT is priced at $22.92 on the NASDAQ, while ASND trades at $261.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ADPT currently has a P/E ratio of -42.44, whereas ASND's P/E ratio is -107.85. In terms of profitability, ADPT's ROE is -0.24%, compared to ASND's ROE of -56.42%. Regarding short-term risk, ADPT is more volatile compared to ASND. This indicates higher risk in terms of short-term price fluctuations for ADPT.Check ASND's competition here
BridgeBio Pharma, Inc. (NASDAQ: BBIO)
ADPT vs BBIO Comparison July 2026
Adaptive Biotechnologies Corporation (NASDAQ: ADPT) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ADPT stands at 3.7B. In comparison, BBIO has a market cap of 15.9B. Regarding current trading prices, ADPT is priced at $22.92 on the NASDAQ, while BBIO trades at $81.38.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ADPT currently has a P/E ratio of -42.44, whereas BBIO's P/E ratio is -21.76. In terms of profitability, ADPT's ROE is -0.24%, compared to BBIO's ROE of +0.36%. Regarding short-term risk, ADPT is more volatile compared to BBIO. This indicates higher risk in terms of short-term price fluctuations for ADPT.Check BBIO's competition here
Jazz Pharmaceuticals plc (NASDAQ: JAZZ)
ADPT vs JAZZ Comparison July 2026
Adaptive Biotechnologies Corporation (NASDAQ: ADPT) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ADPT stands at 3.7B. In comparison, JAZZ has a market cap of 15.5B. Regarding current trading prices, ADPT is priced at $22.92 on the NASDAQ, while JAZZ trades at $247.53.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ADPT currently has a P/E ratio of -42.44, whereas JAZZ's P/E ratio is 19.25. In terms of profitability, ADPT's ROE is -0.24%, compared to JAZZ's ROE of +0.01%. Regarding short-term risk, ADPT is more volatile compared to JAZZ. This indicates higher risk in terms of short-term price fluctuations for ADPT.Check JAZZ's competition here
Exelixis, Inc. (NASDAQ: EXEL)
ADPT vs EXEL Comparison July 2026
Adaptive Biotechnologies Corporation (NASDAQ: ADPT) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ADPT stands at 3.7B. In comparison, EXEL has a market cap of 14.1B. Regarding current trading prices, ADPT is priced at $22.92 on the NASDAQ, while EXEL trades at $55.92.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ADPT currently has a P/E ratio of -42.44, whereas EXEL's P/E ratio is 16.74. In terms of profitability, ADPT's ROE is -0.24%, compared to EXEL's ROE of +0.40%. Regarding short-term risk, ADPT is more volatile compared to EXEL. This indicates higher risk in terms of short-term price fluctuations for ADPT.Check EXEL's competition here
Madrigal Pharmaceuticals, Inc. (NASDAQ: MDGL)
ADPT vs MDGL Comparison July 2026
Adaptive Biotechnologies Corporation (NASDAQ: ADPT) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ADPT stands at 3.7B. In comparison, MDGL has a market cap of 12.8B. Regarding current trading prices, ADPT is priced at $22.92 on the NASDAQ, while MDGL trades at $553.48.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ADPT currently has a P/E ratio of -42.44, whereas MDGL's P/E ratio is -43.24. In terms of profitability, ADPT's ROE is -0.24%, compared to MDGL's ROE of -0.50%. Regarding short-term risk, ADPT is more volatile compared to MDGL. This indicates higher risk in terms of short-term price fluctuations for ADPT.Check MDGL's competition here
Karuna Therapeutics, Inc. (NASDAQ: KRTX)
ADPT vs KRTX Comparison July 2026
Adaptive Biotechnologies Corporation (NASDAQ: ADPT) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ADPT stands at 3.7B. In comparison, KRTX has a market cap of 12.6B. Regarding current trading prices, ADPT is priced at $22.92 on the NASDAQ, while KRTX trades at $329.83.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ADPT currently has a P/E ratio of -42.44, whereas KRTX's P/E ratio is -28.09. In terms of profitability, ADPT's ROE is -0.24%, compared to KRTX's ROE of -0.36%. Regarding short-term risk, ADPT is more volatile compared to KRTX. This indicates higher risk in terms of short-term price fluctuations for ADPT.Check KRTX's competition here
Axsome Therapeutics, Inc. (NASDAQ: AXSM)
ADPT vs AXSM Comparison July 2026
Adaptive Biotechnologies Corporation (NASDAQ: ADPT) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ADPT stands at 3.7B. In comparison, AXSM has a market cap of 11.8B. Regarding current trading prices, ADPT is priced at $22.92 on the NASDAQ, while AXSM trades at $230.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ADPT currently has a P/E ratio of -42.44, whereas AXSM's P/E ratio is -60.05. In terms of profitability, ADPT's ROE is -0.24%, compared to AXSM's ROE of -2.60%. Regarding short-term risk, ADPT is more volatile compared to AXSM. This indicates higher risk in terms of short-term price fluctuations for ADPT.Check AXSM's competition here
BioMarin Pharmaceutical Inc. (NASDAQ: BMRN)
ADPT vs BMRN Comparison July 2026
Adaptive Biotechnologies Corporation (NASDAQ: ADPT) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ADPT stands at 3.7B. In comparison, BMRN has a market cap of 11.5B. Regarding current trading prices, ADPT is priced at $22.92 on the NASDAQ, while BMRN trades at $59.59.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ADPT currently has a P/E ratio of -42.44, whereas BMRN's P/E ratio is 28.65. In terms of profitability, ADPT's ROE is -0.24%, compared to BMRN's ROE of +0.04%. Regarding short-term risk, ADPT is more volatile compared to BMRN. This indicates higher risk in terms of short-term price fluctuations for ADPT.Check BMRN's competition here
Bio-Techne Corporation (NASDAQ: TECH)
ADPT vs TECH Comparison July 2026
Adaptive Biotechnologies Corporation (NASDAQ: ADPT) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ADPT stands at 3.7B. In comparison, TECH has a market cap of 11.3B. Regarding current trading prices, ADPT is priced at $22.92 on the NASDAQ, while TECH trades at $72.12.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ADPT currently has a P/E ratio of -42.44, whereas TECH's P/E ratio is 37.18. In terms of profitability, ADPT's ROE is -0.24%, compared to TECH's ROE of +0.05%. Regarding short-term risk, ADPT is more volatile compared to TECH. This indicates higher risk in terms of short-term price fluctuations for ADPT.Check TECH's competition here
Avidity Biosciences Inc (NASDAQ: RNAM)
ADPT vs RNAM Comparison July 2026
Adaptive Biotechnologies Corporation (NASDAQ: ADPT) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ADPT stands at 3.7B. In comparison, RNAM has a market cap of 11.3B. Regarding current trading prices, ADPT is priced at $22.92 on the NASDAQ, while RNAM trades at $72.86.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ADPT currently has a P/E ratio of -42.44, whereas RNAM's P/E ratio is -17.39. In terms of profitability, ADPT's ROE is -0.24%, compared to RNAM's ROE of -0.45%. Regarding short-term risk, ADPT is more volatile compared to RNAM. This indicates higher risk in terms of short-term price fluctuations for ADPT.Check RNAM's competition here
Summit Therapeutics Inc. (NASDAQ: SMMT)
ADPT vs SMMT Comparison July 2026
Adaptive Biotechnologies Corporation (NASDAQ: ADPT) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ADPT stands at 3.7B. In comparison, SMMT has a market cap of 10.7B. Regarding current trading prices, ADPT is priced at $22.92 on the NASDAQ, while SMMT trades at $13.81.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ADPT currently has a P/E ratio of -42.44, whereas SMMT's P/E ratio is -8.63. In terms of profitability, ADPT's ROE is -0.24%, compared to SMMT's ROE of -3.41%. Regarding short-term risk, ADPT is more volatile compared to SMMT. This indicates higher risk in terms of short-term price fluctuations for ADPT.Check SMMT's competition here
Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR)
ADPT vs ARWR Comparison July 2026
Adaptive Biotechnologies Corporation (NASDAQ: ADPT) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ADPT stands at 3.7B. In comparison, ARWR has a market cap of 10.5B. Regarding current trading prices, ADPT is priced at $22.92 on the NASDAQ, while ARWR trades at $74.30.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ADPT currently has a P/E ratio of -42.44, whereas ARWR's P/E ratio is -34.56. In terms of profitability, ADPT's ROE is -0.24%, compared to ARWR's ROE of -0.55%. Regarding short-term risk, ADPT is more volatile compared to ARWR. This indicates higher risk in terms of short-term price fluctuations for ADPT.Check ARWR's competition here
Krystal Biotech, Inc. (NASDAQ: KRYS)
ADPT vs KRYS Comparison July 2026
Adaptive Biotechnologies Corporation (NASDAQ: ADPT) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ADPT stands at 3.7B. In comparison, KRYS has a market cap of 10.5B. Regarding current trading prices, ADPT is priced at $22.92 on the NASDAQ, while KRYS trades at $354.86.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ADPT currently has a P/E ratio of -42.44, whereas KRYS's P/E ratio is 47.44. In terms of profitability, ADPT's ROE is -0.24%, compared to KRYS's ROE of +0.19%. Regarding short-term risk, ADPT is more volatile compared to KRYS. This indicates higher risk in terms of short-term price fluctuations for ADPT.Check KRYS's competition here
Abivax S.A. (NASDAQ: ABVX)
ADPT vs ABVX Comparison July 2026
Adaptive Biotechnologies Corporation (NASDAQ: ADPT) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ADPT stands at 3.7B. In comparison, ABVX has a market cap of 10B. Regarding current trading prices, ADPT is priced at $22.92 on the NASDAQ, while ABVX trades at $136.65.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ADPT currently has a P/E ratio of -42.44, whereas ABVX's P/E ratio is -71.63. In terms of profitability, ADPT's ROE is -0.24%, compared to ABVX's ROE of -1.65%. Regarding short-term risk, ADPT is more volatile compared to ABVX. This indicates higher risk in terms of short-term price fluctuations for ADPT.Check ABVX's competition here
Cytokinetics, Incorporated (NASDAQ: CYTK)
ADPT vs CYTK Comparison July 2026
Adaptive Biotechnologies Corporation (NASDAQ: ADPT) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ADPT stands at 3.7B. In comparison, CYTK has a market cap of 10B. Regarding current trading prices, ADPT is priced at $22.92 on the NASDAQ, while CYTK trades at $80.18.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ADPT currently has a P/E ratio of -42.44, whereas CYTK's P/E ratio is -13.75. In terms of profitability, ADPT's ROE is -0.24%, compared to CYTK's ROE of +1.40%. Regarding short-term risk, ADPT is more volatile compared to CYTK. This indicates higher risk in terms of short-term price fluctuations for ADPT.Check CYTK's competition here
Prometheus Biosciences, Inc. (NASDAQ: RXDX)
ADPT vs RXDX Comparison July 2026
Adaptive Biotechnologies Corporation (NASDAQ: ADPT) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ADPT stands at 3.7B. In comparison, RXDX has a market cap of 9.6B. Regarding current trading prices, ADPT is priced at $22.92 on the NASDAQ, while RXDX trades at $199.92.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ADPT currently has a P/E ratio of -42.44, whereas RXDX's P/E ratio is -56.47. In terms of profitability, ADPT's ROE is -0.24%, compared to RXDX's ROE of -0.31%. Regarding short-term risk, ADPT is more volatile compared to RXDX. This indicates higher risk in terms of short-term price fluctuations for ADPT.Check RXDX's competition here
Kymera Therapeutics, Inc. (NASDAQ: KYMR)
ADPT vs KYMR Comparison July 2026
Adaptive Biotechnologies Corporation (NASDAQ: ADPT) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ADPT stands at 3.7B. In comparison, KYMR has a market cap of 9.5B. Regarding current trading prices, ADPT is priced at $22.92 on the NASDAQ, while KYMR trades at $115.77.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ADPT currently has a P/E ratio of -42.44, whereas KYMR's P/E ratio is -32.80. In terms of profitability, ADPT's ROE is -0.24%, compared to KYMR's ROE of -0.25%. Regarding short-term risk, ADPT is more volatile compared to KYMR. This indicates higher risk in terms of short-term price fluctuations for ADPT.Check KYMR's competition here
Halozyme Therapeutics, Inc. (NASDAQ: HALO)
ADPT vs HALO Comparison July 2026
Adaptive Biotechnologies Corporation (NASDAQ: ADPT) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ADPT stands at 3.7B. In comparison, HALO has a market cap of 9.2B. Regarding current trading prices, ADPT is priced at $22.92 on the NASDAQ, while HALO trades at $77.81.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ADPT currently has a P/E ratio of -42.44, whereas HALO's P/E ratio is 16.84. In terms of profitability, ADPT's ROE is -0.24%, compared to HALO's ROE of +1.26%. Regarding short-term risk, ADPT is more volatile compared to HALO. This indicates higher risk in terms of short-term price fluctuations for ADPT.Check HALO's competition here
Nuvalent, Inc. (NASDAQ: NUVL)
ADPT vs NUVL Comparison July 2026
Adaptive Biotechnologies Corporation (NASDAQ: ADPT) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ADPT stands at 3.7B. In comparison, NUVL has a market cap of 9.1B. Regarding current trading prices, ADPT is priced at $22.92 on the NASDAQ, while NUVL trades at $123.96.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ADPT currently has a P/E ratio of -42.44, whereas NUVL's P/E ratio is -21.79. In terms of profitability, ADPT's ROE is -0.24%, compared to NUVL's ROE of -0.43%. Regarding short-term risk, ADPT is more volatile compared to NUVL. This indicates higher risk in terms of short-term price fluctuations for ADPT.Check NUVL's competition here
Protagonist Therapeutics, Inc. (NASDAQ: PTGX)
ADPT vs PTGX Comparison July 2026
Adaptive Biotechnologies Corporation (NASDAQ: ADPT) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ADPT stands at 3.7B. In comparison, PTGX has a market cap of 9.1B. Regarding current trading prices, ADPT is priced at $22.92 on the NASDAQ, while PTGX trades at $140.91.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ADPT currently has a P/E ratio of -42.44, whereas PTGX's P/E ratio is -77.92. In terms of profitability, ADPT's ROE is -0.24%, compared to PTGX's ROE of -0.18%. Regarding short-term risk, ADPT is more volatile compared to PTGX. This indicates higher risk in terms of short-term price fluctuations for ADPT.Check PTGX's competition here
Ionis Pharmaceuticals, Inc. (NASDAQ: IONS)
ADPT vs IONS Comparison July 2026
Adaptive Biotechnologies Corporation (NASDAQ: ADPT) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ADPT stands at 3.7B. In comparison, IONS has a market cap of 9B. Regarding current trading prices, ADPT is priced at $22.92 on the NASDAQ, while IONS trades at $54.39.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ADPT currently has a P/E ratio of -42.44, whereas IONS's P/E ratio is -31.77. In terms of profitability, ADPT's ROE is -0.24%, compared to IONS's ROE of -0.59%. Regarding short-term risk, ADPT is more volatile compared to IONS. This indicates higher risk in terms of short-term price fluctuations for ADPT.Check IONS's competition here
Crinetics Pharmaceuticals, Inc. (NASDAQ: CRNX)
ADPT vs CRNX Comparison July 2026
Adaptive Biotechnologies Corporation (NASDAQ: ADPT) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ADPT stands at 3.7B. In comparison, CRNX has a market cap of 8.9B. Regarding current trading prices, ADPT is priced at $22.92 on the NASDAQ, while CRNX trades at $83.86.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ADPT currently has a P/E ratio of -42.44, whereas CRNX's P/E ratio is -16.35. In terms of profitability, ADPT's ROE is -0.24%, compared to CRNX's ROE of -0.44%. Regarding short-term risk, ADPT is more volatile compared to CRNX. This indicates higher risk in terms of short-term price fluctuations for ADPT.Check CRNX's competition here
Alkermes plc (NASDAQ: ALKS)
ADPT vs ALKS Comparison July 2026
Adaptive Biotechnologies Corporation (NASDAQ: ADPT) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ADPT stands at 3.7B. In comparison, ALKS has a market cap of 8.8B. Regarding current trading prices, ADPT is priced at $22.92 on the NASDAQ, while ALKS trades at $52.72.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ADPT currently has a P/E ratio of -42.44, whereas ALKS's P/E ratio is 55.49. In terms of profitability, ADPT's ROE is -0.24%, compared to ALKS's ROE of +0.09%. Regarding short-term risk, ADPT is more volatile compared to ALKS. This indicates higher risk in terms of short-term price fluctuations for ADPT.Check ALKS's competition here
ImmunoGen, Inc. (NASDAQ: IMGN)
ADPT vs IMGN Comparison July 2026
Adaptive Biotechnologies Corporation (NASDAQ: ADPT) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ADPT stands at 3.7B. In comparison, IMGN has a market cap of 8.7B. Regarding current trading prices, ADPT is priced at $22.92 on the NASDAQ, while IMGN trades at $31.24.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ADPT currently has a P/E ratio of -42.44, whereas IMGN's P/E ratio is -111.55. In terms of profitability, ADPT's ROE is -0.24%, compared to IMGN's ROE of -0.93%. Regarding short-term risk, ADPT is more volatile compared to IMGN. This indicates higher risk in terms of short-term price fluctuations for ADPT.Check IMGN's competition here
TG Therapeutics, Inc. (NASDAQ: TGTX)
ADPT vs TGTX Comparison July 2026
Adaptive Biotechnologies Corporation (NASDAQ: ADPT) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ADPT stands at 3.7B. In comparison, TGTX has a market cap of 8.4B. Regarding current trading prices, ADPT is priced at $22.92 on the NASDAQ, while TGTX trades at $54.87.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ADPT currently has a P/E ratio of -42.44, whereas TGTX's P/E ratio is 18.85. In terms of profitability, ADPT's ROE is -0.24%, compared to TGTX's ROE of +0.87%. Regarding short-term risk, ADPT is more volatile compared to TGTX. This indicates higher risk in terms of short-term price fluctuations for ADPT.Check TGTX's competition here
Blueprint Medicines Corporation (NASDAQ: BPMC)
ADPT vs BPMC Comparison July 2026
Adaptive Biotechnologies Corporation (NASDAQ: ADPT) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ADPT stands at 3.7B. In comparison, BPMC has a market cap of 8.4B. Regarding current trading prices, ADPT is priced at $22.92 on the NASDAQ, while BPMC trades at $129.46.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ADPT currently has a P/E ratio of -42.44, whereas BPMC's P/E ratio is -51.58. In terms of profitability, ADPT's ROE is -0.24%, compared to BPMC's ROE of -0.31%. Regarding short-term risk, ADPT is more volatile compared to BPMC. This indicates higher risk in terms of short-term price fluctuations for ADPT.Check BPMC's competition here
Apogee Therapeutics, Inc. (NASDAQ: APGE)
ADPT vs APGE Comparison July 2026
Adaptive Biotechnologies Corporation (NASDAQ: ADPT) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ADPT stands at 3.7B. In comparison, APGE has a market cap of 8.3B. Regarding current trading prices, ADPT is priced at $22.92 on the NASDAQ, while APGE trades at $134.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ADPT currently has a P/E ratio of -42.44, whereas APGE's P/E ratio is -30.95. In terms of profitability, ADPT's ROE is -0.24%, compared to APGE's ROE of -0.33%. Regarding short-term risk, ADPT is more volatile compared to APGE. This indicates higher risk in terms of short-term price fluctuations for ADPT.Check APGE's competition here
Cerevel Therapeutics Holdings, Inc. (NASDAQ: CERE)
ADPT vs CERE Comparison July 2026
Adaptive Biotechnologies Corporation (NASDAQ: ADPT) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ADPT stands at 3.7B. In comparison, CERE has a market cap of 8.2B. Regarding current trading prices, ADPT is priced at $22.92 on the NASDAQ, while CERE trades at $44.96.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ADPT currently has a P/E ratio of -42.44, whereas CERE's P/E ratio is -16.47. In terms of profitability, ADPT's ROE is -0.24%, compared to CERE's ROE of -0.72%. Regarding short-term risk, ADPT is more volatile compared to CERE. This indicates higher risk in terms of short-term price fluctuations for ADPT.Check CERE's competition here
Vaxcyte, Inc. (NASDAQ: PCVX)
ADPT vs PCVX Comparison July 2026
Adaptive Biotechnologies Corporation (NASDAQ: ADPT) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ADPT stands at 3.7B. In comparison, PCVX has a market cap of 8.1B. Regarding current trading prices, ADPT is priced at $22.92 on the NASDAQ, while PCVX trades at $56.20.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ADPT currently has a P/E ratio of -42.44, whereas PCVX's P/E ratio is -8.17. In terms of profitability, ADPT's ROE is -0.24%, compared to PCVX's ROE of -0.33%. Regarding short-term risk, ADPT is more volatile compared to PCVX. This indicates higher risk in terms of short-term price fluctuations for ADPT.Check PCVX's competition here
Immunovant, Inc. (NASDAQ: IMVT)
ADPT vs IMVT Comparison July 2026
Adaptive Biotechnologies Corporation (NASDAQ: ADPT) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ADPT stands at 3.7B. In comparison, IMVT has a market cap of 8B. Regarding current trading prices, ADPT is priced at $22.92 on the NASDAQ, while IMVT trades at $40.26.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ADPT currently has a P/E ratio of -42.44, whereas IMVT's P/E ratio is -14.59. In terms of profitability, ADPT's ROE is -0.24%, compared to IMVT's ROE of -0.68%. Regarding short-term risk, ADPT is more volatile compared to IMVT. This indicates higher risk in terms of short-term price fluctuations for ADPT.Check IMVT's competition here
ImmunityBio, Inc. (NASDAQ: IBRX)
ADPT vs IBRX Comparison July 2026
Adaptive Biotechnologies Corporation (NASDAQ: ADPT) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ADPT stands at 3.7B. In comparison, IBRX has a market cap of 7.8B. Regarding current trading prices, ADPT is priced at $22.92 on the NASDAQ, while IBRX trades at $7.68.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ADPT currently has a P/E ratio of -42.44, whereas IBRX's P/E ratio is -8.76. In terms of profitability, ADPT's ROE is -0.24%, compared to IBRX's ROE of +1.39%. Regarding short-term risk, ADPT is more volatile compared to IBRX. This indicates higher risk in terms of short-term price fluctuations for ADPT.Check IBRX's competition here
Metsera, Inc. (NASDAQ: MTSR)
ADPT vs MTSR Comparison July 2026
Adaptive Biotechnologies Corporation (NASDAQ: ADPT) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ADPT stands at 3.7B. In comparison, MTSR has a market cap of 7.4B. Regarding current trading prices, ADPT is priced at $22.92 on the NASDAQ, while MTSR trades at $70.50.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ADPT currently has a P/E ratio of -42.44, whereas MTSR's P/E ratio is -23.58. In terms of profitability, ADPT's ROE is -0.24%, compared to MTSR's ROE of -0.61%. Regarding short-term risk, ADPT is more volatile compared to MTSR. This indicates higher risk in terms of short-term price fluctuations for ADPT.Check MTSR's competition here
Rhythm Pharmaceuticals, Inc. (NASDAQ: RYTM)
ADPT vs RYTM Comparison July 2026
Adaptive Biotechnologies Corporation (NASDAQ: ADPT) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ADPT stands at 3.7B. In comparison, RYTM has a market cap of 7.3B. Regarding current trading prices, ADPT is priced at $22.92 on the NASDAQ, while RYTM trades at $106.60.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ADPT currently has a P/E ratio of -42.44, whereas RYTM's P/E ratio is -34.06. In terms of profitability, ADPT's ROE is -0.24%, compared to RYTM's ROE of -2.03%. Regarding short-term risk, ADPT is more volatile compared to RYTM. This indicates higher risk in terms of short-term price fluctuations for ADPT.Check RYTM's competition here
Merus N.V. (NASDAQ: MRUS)
ADPT vs MRUS Comparison July 2026
Adaptive Biotechnologies Corporation (NASDAQ: ADPT) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ADPT stands at 3.7B. In comparison, MRUS has a market cap of 6.8B. Regarding current trading prices, ADPT is priced at $22.92 on the NASDAQ, while MRUS trades at $90.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ADPT currently has a P/E ratio of -42.44, whereas MRUS's P/E ratio is -17.05. In terms of profitability, ADPT's ROE is -0.24%, compared to MRUS's ROE of -0.46%. Regarding short-term risk, ADPT is more volatile compared to MRUS. This indicates higher risk in terms of short-term price fluctuations for ADPT.Check MRUS's competition here
Arcellx, Inc. (NASDAQ: ACLX)
ADPT vs ACLX Comparison July 2026
Adaptive Biotechnologies Corporation (NASDAQ: ADPT) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ADPT stands at 3.7B. In comparison, ACLX has a market cap of 6.7B. Regarding current trading prices, ADPT is priced at $22.92 on the NASDAQ, while ACLX trades at $115.07.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ADPT currently has a P/E ratio of -42.44, whereas ACLX's P/E ratio is -28.27. In terms of profitability, ADPT's ROE is -0.24%, compared to ACLX's ROE of -0.55%. Regarding short-term risk, ADPT is more volatile compared to ACLX. This indicates higher risk in terms of short-term price fluctuations for ADPT.Check ACLX's competition here
Cogent Biosciences, Inc. (NASDAQ: COGT)
ADPT vs COGT Comparison July 2026
Adaptive Biotechnologies Corporation (NASDAQ: ADPT) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ADPT stands at 3.7B. In comparison, COGT has a market cap of 6.7B. Regarding current trading prices, ADPT is priced at $22.92 on the NASDAQ, while COGT trades at $39.08.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ADPT currently has a P/E ratio of -42.44, whereas COGT's P/E ratio is -18.52. In terms of profitability, ADPT's ROE is -0.24%, compared to COGT's ROE of -0.83%. Regarding short-term risk, ADPT is more volatile compared to COGT. This indicates higher risk in terms of short-term price fluctuations for ADPT.Check COGT's competition here
Praxis Precision Medicines, Inc. (NASDAQ: PRAX)
ADPT vs PRAX Comparison July 2026
Adaptive Biotechnologies Corporation (NASDAQ: ADPT) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ADPT stands at 3.7B. In comparison, PRAX has a market cap of 6.6B. Regarding current trading prices, ADPT is priced at $22.92 on the NASDAQ, while PRAX trades at $314.41.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ADPT currently has a P/E ratio of -42.44, whereas PRAX's P/E ratio is -23.51. In terms of profitability, ADPT's ROE is -0.24%, compared to PRAX's ROE of -0.43%. Regarding short-term risk, ADPT is more volatile compared to PRAX. This indicates higher risk in terms of short-term price fluctuations for ADPT.Check PRAX's competition here
Reata Pharmaceuticals, Inc. (NASDAQ: RETA)
ADPT vs RETA Comparison July 2026
Adaptive Biotechnologies Corporation (NASDAQ: ADPT) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ADPT stands at 3.7B. In comparison, RETA has a market cap of 6.6B. Regarding current trading prices, ADPT is priced at $22.92 on the NASDAQ, while RETA trades at $172.36.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ADPT currently has a P/E ratio of -42.44, whereas RETA's P/E ratio is -66.29. In terms of profitability, ADPT's ROE is -0.24%, compared to RETA's ROE of +0.47%. Regarding short-term risk, ADPT is more volatile compared to RETA. This indicates higher risk in terms of short-term price fluctuations for ADPT.Check RETA's competition here
PTC Therapeutics, Inc. (NASDAQ: PTCT)
ADPT vs PTCT Comparison July 2026
Adaptive Biotechnologies Corporation (NASDAQ: ADPT) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ADPT stands at 3.7B. In comparison, PTCT has a market cap of 6.5B. Regarding current trading prices, ADPT is priced at $22.92 on the NASDAQ, while PTCT trades at $78.59.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ADPT currently has a P/E ratio of -42.44, whereas PTCT's P/E ratio is -33.73. In terms of profitability, ADPT's ROE is -0.24%, compared to PTCT's ROE of +1.00%. Regarding short-term risk, ADPT is more volatile compared to PTCT. This indicates higher risk in terms of short-term price fluctuations for ADPT.Check PTCT's competition here
CG Oncology Inc. (NASDAQ: CGON)
ADPT vs CGON Comparison July 2026
Adaptive Biotechnologies Corporation (NASDAQ: ADPT) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ADPT stands at 3.7B. In comparison, CGON has a market cap of 6.3B. Regarding current trading prices, ADPT is priced at $22.92 on the NASDAQ, while CGON trades at $71.85.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ADPT currently has a P/E ratio of -42.44, whereas CGON's P/E ratio is -30.84. In terms of profitability, ADPT's ROE is -0.24%, compared to CGON's ROE of -0.23%. Regarding short-term risk, ADPT is more volatile compared to CGON. This indicates higher risk in terms of short-term price fluctuations for ADPT.Check CGON's competition here
Scholar Rock Holding Corporation (NASDAQ: SRRK)
ADPT vs SRRK Comparison July 2026
Adaptive Biotechnologies Corporation (NASDAQ: ADPT) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ADPT stands at 3.7B. In comparison, SRRK has a market cap of 6.3B. Regarding current trading prices, ADPT is priced at $22.92 on the NASDAQ, while SRRK trades at $52.86.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ADPT currently has a P/E ratio of -42.44, whereas SRRK's P/E ratio is -14.72. In terms of profitability, ADPT's ROE is -0.24%, compared to SRRK's ROE of -1.64%. Regarding short-term risk, ADPT is more volatile compared to SRRK. This indicates higher risk in terms of short-term price fluctuations for ADPT.Check SRRK's competition here
Centessa Pharmaceuticals plc (NASDAQ: CNTA)
ADPT vs CNTA Comparison July 2026
Adaptive Biotechnologies Corporation (NASDAQ: ADPT) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ADPT stands at 3.7B. In comparison, CNTA has a market cap of 6.3B. Regarding current trading prices, ADPT is priced at $22.92 on the NASDAQ, while CNTA trades at $40.50.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ADPT currently has a P/E ratio of -42.44, whereas CNTA's P/E ratio is -22.63. In terms of profitability, ADPT's ROE is -0.24%, compared to CNTA's ROE of -0.60%. Regarding short-term risk, ADPT is more volatile compared to CNTA. This indicates higher risk in terms of short-term price fluctuations for ADPT.Check CNTA's competition here
Ligand Pharmaceuticals Incorporated (NASDAQ: LGND)
ADPT vs LGND Comparison July 2026
Adaptive Biotechnologies Corporation (NASDAQ: ADPT) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ADPT stands at 3.7B. In comparison, LGND has a market cap of 6.1B. Regarding current trading prices, ADPT is priced at $22.92 on the NASDAQ, while LGND trades at $303.39.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ADPT currently has a P/E ratio of -42.44, whereas LGND's P/E ratio is 36.38. In terms of profitability, ADPT's ROE is -0.24%, compared to LGND's ROE of +0.16%. Regarding short-term risk, ADPT is more volatile compared to LGND. This indicates higher risk in terms of short-term price fluctuations for ADPT.Check LGND's competition here
Spyre Therapeutics, Inc. (NASDAQ: SYRE)
ADPT vs SYRE Comparison July 2026
Adaptive Biotechnologies Corporation (NASDAQ: ADPT) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ADPT stands at 3.7B. In comparison, SYRE has a market cap of 6B. Regarding current trading prices, ADPT is priced at $22.92 on the NASDAQ, while SYRE trades at $100.23.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ADPT currently has a P/E ratio of -42.44, whereas SYRE's P/E ratio is -48.11. In terms of profitability, ADPT's ROE is -0.24%, compared to SYRE's ROE of -0.31%. Regarding short-term risk, ADPT is less volatile compared to SYRE. This indicates lower risk in terms of short-term price fluctuations for ADPT.Check SYRE's competition here
Belite Bio, Inc (NASDAQ: BLTE)
ADPT vs BLTE Comparison July 2026
Adaptive Biotechnologies Corporation (NASDAQ: ADPT) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ADPT stands at 3.7B. In comparison, BLTE has a market cap of 6B. Regarding current trading prices, ADPT is priced at $22.92 on the NASDAQ, while BLTE trades at $150.08.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ADPT currently has a P/E ratio of -42.44, whereas BLTE's P/E ratio is -80.26. In terms of profitability, ADPT's ROE is -0.24%, compared to BLTE's ROE of -0.18%. Regarding short-term risk, ADPT is more volatile compared to BLTE. This indicates higher risk in terms of short-term price fluctuations for ADPT.Check BLTE's competition here
Mirum Pharmaceuticals, Inc. (NASDAQ: MIRM)
ADPT vs MIRM Comparison July 2026
Adaptive Biotechnologies Corporation (NASDAQ: ADPT) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ADPT stands at 3.7B. In comparison, MIRM has a market cap of 6B. Regarding current trading prices, ADPT is priced at $22.92 on the NASDAQ, while MIRM trades at $118.86.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ADPT currently has a P/E ratio of -42.44, whereas MIRM's P/E ratio is -8.73. In terms of profitability, ADPT's ROE is -0.24%, compared to MIRM's ROE of -2.89%. Regarding short-term risk, ADPT is more volatile compared to MIRM. This indicates higher risk in terms of short-term price fluctuations for ADPT.Check MIRM's competition here
Erasca, Inc. (NASDAQ: ERAS)
ADPT vs ERAS Comparison July 2026
Adaptive Biotechnologies Corporation (NASDAQ: ADPT) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ADPT stands at 3.7B. In comparison, ERAS has a market cap of 6B. Regarding current trading prices, ADPT is priced at $22.92 on the NASDAQ, while ERAS trades at $19.17.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ADPT currently has a P/E ratio of -42.44, whereas ERAS's P/E ratio is -20.61. In terms of profitability, ADPT's ROE is -0.24%, compared to ERAS's ROE of -0.77%. Regarding short-term risk, ADPT is less volatile compared to ERAS. This indicates lower risk in terms of short-term price fluctuations for ADPT.Check ERAS's competition here
Cidara Therapeutics, Inc. (NASDAQ: CDTX)
ADPT vs CDTX Comparison July 2026
Adaptive Biotechnologies Corporation (NASDAQ: ADPT) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ADPT stands at 3.7B. In comparison, CDTX has a market cap of 5.6B. Regarding current trading prices, ADPT is priced at $22.92 on the NASDAQ, while CDTX trades at $221.38.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ADPT currently has a P/E ratio of -42.44, whereas CDTX's P/E ratio is -19.77. In terms of profitability, ADPT's ROE is -0.24%, compared to CDTX's ROE of -0.37%. Regarding short-term risk, ADPT is more volatile compared to CDTX. This indicates higher risk in terms of short-term price fluctuations for ADPT.Check CDTX's competition here
Abcam plc (NASDAQ: ABCM)
ADPT vs ABCM Comparison July 2026
Adaptive Biotechnologies Corporation (NASDAQ: ADPT) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ADPT stands at 3.7B. In comparison, ABCM has a market cap of 5.5B. Regarding current trading prices, ADPT is priced at $22.92 on the NASDAQ, while ABCM trades at $23.99.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ADPT currently has a P/E ratio of -42.44, whereas ABCM's P/E ratio is 2399.00. In terms of profitability, ADPT's ROE is -0.24%, compared to ABCM's ROE of -0.01%. Regarding short-term risk, ADPT is more volatile compared to ABCM. This indicates higher risk in terms of short-term price fluctuations for ADPT.Check ABCM's competition here
IVERIC bio, Inc. (NASDAQ: ISEE)
ADPT vs ISEE Comparison July 2026
Adaptive Biotechnologies Corporation (NASDAQ: ADPT) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ADPT stands at 3.7B. In comparison, ISEE has a market cap of 5.5B. Regarding current trading prices, ADPT is priced at $22.92 on the NASDAQ, while ISEE trades at $39.95.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ADPT currently has a P/E ratio of -42.44, whereas ISEE's P/E ratio is -22.44. In terms of profitability, ADPT's ROE is -0.24%, compared to ISEE's ROE of -0.39%. Regarding short-term risk, ADPT is more volatile compared to ISEE. This indicates higher risk in terms of short-term price fluctuations for ADPT.Check ISEE's competition here
Xenon Pharmaceuticals Inc. (NASDAQ: XENE)
ADPT vs XENE Comparison July 2026
Adaptive Biotechnologies Corporation (NASDAQ: ADPT) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ADPT stands at 3.7B. In comparison, XENE has a market cap of 5.4B. Regarding current trading prices, ADPT is priced at $22.92 on the NASDAQ, while XENE trades at $68.26.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ADPT currently has a P/E ratio of -42.44, whereas XENE's P/E ratio is -14.52. In terms of profitability, ADPT's ROE is -0.24%, compared to XENE's ROE of -0.49%. Regarding short-term risk, ADPT is more volatile compared to XENE. This indicates higher risk in terms of short-term price fluctuations for ADPT.Check XENE's competition here
Travere Therapeutics, Inc. (NASDAQ: TVTX)
ADPT vs TVTX Comparison July 2026
Adaptive Biotechnologies Corporation (NASDAQ: ADPT) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ADPT stands at 3.7B. In comparison, TVTX has a market cap of 5.3B. Regarding current trading prices, ADPT is priced at $22.92 on the NASDAQ, while TVTX trades at $56.71.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ADPT currently has a P/E ratio of -42.44, whereas TVTX's P/E ratio is -257.77. In terms of profitability, ADPT's ROE is -0.24%, compared to TVTX's ROE of -0.27%. Regarding short-term risk, ADPT is less volatile compared to TVTX. This indicates lower risk in terms of short-term price fluctuations for ADPT.Check TVTX's competition here
Apellis Pharmaceuticals, Inc. (NASDAQ: APLS)
ADPT vs APLS Comparison July 2026
Adaptive Biotechnologies Corporation (NASDAQ: ADPT) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ADPT stands at 3.7B. In comparison, APLS has a market cap of 5.3B. Regarding current trading prices, ADPT is priced at $22.92 on the NASDAQ, while APLS trades at $41.03.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ADPT currently has a P/E ratio of -42.44, whereas APLS's P/E ratio is 38.35. In terms of profitability, ADPT's ROE is -0.24%, compared to APLS's ROE of +0.40%. Regarding short-term risk, ADPT is more volatile compared to APLS. This indicates higher risk in terms of short-term price fluctuations for ADPT.Check APLS's competition here
Definium Therapeutics, Inc. (NASDAQ: DFTX)
ADPT vs DFTX Comparison July 2026
Adaptive Biotechnologies Corporation (NASDAQ: ADPT) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ADPT stands at 3.7B. In comparison, DFTX has a market cap of 4.8B. Regarding current trading prices, ADPT is priced at $22.92 on the NASDAQ, while DFTX trades at $44.29.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ADPT currently has a P/E ratio of -42.44, whereas DFTX's P/E ratio is N/A. In terms of profitability, ADPT's ROE is -0.24%, compared to DFTX's ROE of -1.02%. Regarding short-term risk, ADPT is more volatile compared to DFTX. This indicates higher risk in terms of short-term price fluctuations for ADPT.Check DFTX's competition here
Terns Pharmaceuticals, Inc. (NASDAQ: TERN)
ADPT vs TERN Comparison July 2026
Adaptive Biotechnologies Corporation (NASDAQ: ADPT) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ADPT stands at 3.7B. In comparison, TERN has a market cap of 4.8B. Regarding current trading prices, ADPT is priced at $22.92 on the NASDAQ, while TERN trades at $52.95.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ADPT currently has a P/E ratio of -42.44, whereas TERN's P/E ratio is -51.41. In terms of profitability, ADPT's ROE is -0.24%, compared to TERN's ROE of -0.20%. Regarding short-term risk, ADPT is more volatile compared to TERN. This indicates higher risk in terms of short-term price fluctuations for ADPT.Check TERN's competition here
Caris Life Sciences, Inc. (NASDAQ: CAI)
ADPT vs CAI Comparison July 2026
Adaptive Biotechnologies Corporation (NASDAQ: ADPT) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ADPT stands at 3.7B. In comparison, CAI has a market cap of 4.7B. Regarding current trading prices, ADPT is priced at $22.92 on the NASDAQ, while CAI trades at $16.49.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ADPT currently has a P/E ratio of -42.44, whereas CAI's P/E ratio is -90.70. In terms of profitability, ADPT's ROE is -0.24%, compared to CAI's ROE of +0.06%. Regarding short-term risk, ADPT is more volatile compared to CAI. This indicates higher risk in terms of short-term price fluctuations for ADPT.Check CAI's competition here
Veradermics, Incorporated (NYSE: MANE)
ADPT vs MANE Comparison July 2026
Adaptive Biotechnologies Corporation (NASDAQ: ADPT) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ADPT stands at 3.7B. In comparison, MANE has a market cap of 4.7B. Regarding current trading prices, ADPT is priced at $22.92 on the NASDAQ, while MANE trades at $111.32.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ADPT currently has a P/E ratio of -42.44, whereas MANE's P/E ratio is -35.47. In terms of profitability, ADPT's ROE is -0.24%, compared to MANE's ROE of -0.84%. Regarding short-term risk, ADPT is less volatile compared to MANE. This indicates lower risk in terms of short-term price fluctuations for ADPT.Check MANE's competition here
CRISPR Therapeutics AG (NASDAQ: CRSP)
ADPT vs CRSP Comparison July 2026
Adaptive Biotechnologies Corporation (NASDAQ: ADPT) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ADPT stands at 3.7B. In comparison, CRSP has a market cap of 4.6B. Regarding current trading prices, ADPT is priced at $22.92 on the NASDAQ, while CRSP trades at $47.78.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ADPT currently has a P/E ratio of -42.44, whereas CRSP's P/E ratio is -9.35. In terms of profitability, ADPT's ROE is -0.24%, compared to CRSP's ROE of -0.31%. Regarding short-term risk, ADPT is more volatile compared to CRSP. This indicates higher risk in terms of short-term price fluctuations for ADPT.Check CRSP's competition here
Amicus Therapeutics, Inc. (NASDAQ: FOLD)
ADPT vs FOLD Comparison July 2026
Adaptive Biotechnologies Corporation (NASDAQ: ADPT) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ADPT stands at 3.7B. In comparison, FOLD has a market cap of 4.5B. Regarding current trading prices, ADPT is priced at $22.92 on the NASDAQ, while FOLD trades at $14.49.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ADPT currently has a P/E ratio of -42.44, whereas FOLD's P/E ratio is -161.00. In terms of profitability, ADPT's ROE is -0.24%, compared to FOLD's ROE of -0.12%. Regarding short-term risk, ADPT is more volatile compared to FOLD. This indicates higher risk in terms of short-term price fluctuations for ADPT.Check FOLD's competition here
Akero Therapeutics, Inc. (NASDAQ: AKRO)
ADPT vs AKRO Comparison July 2026
Adaptive Biotechnologies Corporation (NASDAQ: ADPT) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ADPT stands at 3.7B. In comparison, AKRO has a market cap of 4.5B. Regarding current trading prices, ADPT is priced at $22.92 on the NASDAQ, while AKRO trades at $54.65.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ADPT currently has a P/E ratio of -42.44, whereas AKRO's P/E ratio is -14.57. In terms of profitability, ADPT's ROE is -0.24%, compared to AKRO's ROE of -0.22%. Regarding short-term risk, ADPT is more volatile compared to AKRO. This indicates higher risk in terms of short-term price fluctuations for ADPT.Check AKRO's competition here
Alpine Immune Sciences, Inc. (NASDAQ: ALPN)
ADPT vs ALPN Comparison July 2026
Adaptive Biotechnologies Corporation (NASDAQ: ADPT) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ADPT stands at 3.7B. In comparison, ALPN has a market cap of 4.5B. Regarding current trading prices, ADPT is priced at $22.92 on the NASDAQ, while ALPN trades at $64.97.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ADPT currently has a P/E ratio of -42.44, whereas ALPN's P/E ratio is -101.52. In terms of profitability, ADPT's ROE is -0.24%, compared to ALPN's ROE of -0.13%. Regarding short-term risk, ADPT is more volatile compared to ALPN. This indicates higher risk in terms of short-term price fluctuations for ADPT.Check ALPN's competition here
Dianthus Therapeutics, Inc. (NASDAQ: DNTH)
ADPT vs DNTH Comparison July 2026
Adaptive Biotechnologies Corporation (NASDAQ: ADPT) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ADPT stands at 3.7B. In comparison, DNTH has a market cap of 4.4B. Regarding current trading prices, ADPT is priced at $22.92 on the NASDAQ, while DNTH trades at $105.60.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ADPT currently has a P/E ratio of -42.44, whereas DNTH's P/E ratio is -25.57. In terms of profitability, ADPT's ROE is -0.24%, compared to DNTH's ROE of -0.02%. Regarding short-term risk, ADPT is less volatile compared to DNTH. This indicates lower risk in terms of short-term price fluctuations for ADPT.Check DNTH's competition here
ACADIA Pharmaceuticals Inc. (NASDAQ: ACAD)
ADPT vs ACAD Comparison July 2026
Adaptive Biotechnologies Corporation (NASDAQ: ADPT) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ADPT stands at 3.7B. In comparison, ACAD has a market cap of 4.4B. Regarding current trading prices, ADPT is priced at $22.92 on the NASDAQ, while ACAD trades at $25.60.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ADPT currently has a P/E ratio of -42.44, whereas ACAD's P/E ratio is 12.55. In terms of profitability, ADPT's ROE is -0.24%, compared to ACAD's ROE of +0.36%. Regarding short-term risk, ADPT is more volatile compared to ACAD. This indicates higher risk in terms of short-term price fluctuations for ADPT.Check ACAD's competition here
Celcuity Inc. (NASDAQ: CELC)
ADPT vs CELC Comparison July 2026
Adaptive Biotechnologies Corporation (NASDAQ: ADPT) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ADPT stands at 3.7B. In comparison, CELC has a market cap of 4.3B. Regarding current trading prices, ADPT is priced at $22.92 on the NASDAQ, while CELC trades at $88.38.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ADPT currently has a P/E ratio of -42.44, whereas CELC's P/E ratio is -22.66. In terms of profitability, ADPT's ROE is -0.24%, compared to CELC's ROE of -2.45%. Regarding short-term risk, ADPT is more volatile compared to CELC. This indicates higher risk in terms of short-term price fluctuations for ADPT.Check CELC's competition here
Viking Therapeutics, Inc. (NASDAQ: VKTX)
ADPT vs VKTX Comparison July 2026
Adaptive Biotechnologies Corporation (NASDAQ: ADPT) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ADPT stands at 3.7B. In comparison, VKTX has a market cap of 4.3B. Regarding current trading prices, ADPT is priced at $22.92 on the NASDAQ, while VKTX trades at $37.08.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ADPT currently has a P/E ratio of -42.44, whereas VKTX's P/E ratio is -8.96. In terms of profitability, ADPT's ROE is -0.24%, compared to VKTX's ROE of -0.71%. Regarding short-term risk, ADPT is more volatile compared to VKTX. This indicates higher risk in terms of short-term price fluctuations for ADPT.Check VKTX's competition here
Edgewise Therapeutics, Inc. (NASDAQ: EWTX)
ADPT vs EWTX Comparison July 2026
Adaptive Biotechnologies Corporation (NASDAQ: ADPT) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ADPT stands at 3.7B. In comparison, EWTX has a market cap of 4.3B. Regarding current trading prices, ADPT is priced at $22.92 on the NASDAQ, while EWTX trades at $39.76.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ADPT currently has a P/E ratio of -42.44, whereas EWTX's P/E ratio is -23.95. In terms of profitability, ADPT's ROE is -0.24%, compared to EWTX's ROE of -0.33%. Regarding short-term risk, ADPT is less volatile compared to EWTX. This indicates lower risk in terms of short-term price fluctuations for ADPT.Check EWTX's competition here
Opthea Limited (NASDAQ: OPT)
ADPT vs OPT Comparison July 2026
Adaptive Biotechnologies Corporation (NASDAQ: ADPT) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ADPT stands at 3.7B. In comparison, OPT has a market cap of 4.2B. Regarding current trading prices, ADPT is priced at $22.92 on the NASDAQ, while OPT trades at $3.41.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ADPT currently has a P/E ratio of -42.44, whereas OPT's P/E ratio is -1.52. In terms of profitability, ADPT's ROE is -0.24%, compared to OPT's ROE of +1.18%. Regarding short-term risk, ADPT is more volatile compared to OPT. This indicates higher risk in terms of short-term price fluctuations for ADPT.Check OPT's competition here
Mirati Therapeutics, Inc. (NASDAQ: MRTX)
ADPT vs MRTX Comparison July 2026
Adaptive Biotechnologies Corporation (NASDAQ: ADPT) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ADPT stands at 3.7B. In comparison, MRTX has a market cap of 4.1B. Regarding current trading prices, ADPT is priced at $22.92 on the NASDAQ, while MRTX trades at $58.70.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ADPT currently has a P/E ratio of -42.44, whereas MRTX's P/E ratio is -4.82. In terms of profitability, ADPT's ROE is -0.24%, compared to MRTX's ROE of -0.62%. Regarding short-term risk, ADPT is more volatile compared to MRTX. This indicates higher risk in terms of short-term price fluctuations for ADPT.Check MRTX's competition here
Legend Biotech Corporation (NASDAQ: LEGN)
ADPT vs LEGN Comparison July 2026
Adaptive Biotechnologies Corporation (NASDAQ: ADPT) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ADPT stands at 3.7B. In comparison, LEGN has a market cap of 4.1B. Regarding current trading prices, ADPT is priced at $22.92 on the NASDAQ, while LEGN trades at $22.26.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ADPT currently has a P/E ratio of -42.44, whereas LEGN's P/E ratio is -32.74. In terms of profitability, ADPT's ROE is -0.24%, compared to LEGN's ROE of -0.25%. Regarding short-term risk, ADPT is more volatile compared to LEGN. This indicates higher risk in terms of short-term price fluctuations for ADPT.Check LEGN's competition here
Dyne Therapeutics, Inc. (NASDAQ: DYN)
ADPT vs DYN Comparison July 2026
Adaptive Biotechnologies Corporation (NASDAQ: ADPT) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ADPT stands at 3.7B. In comparison, DYN has a market cap of 3.9B. Regarding current trading prices, ADPT is priced at $22.92 on the NASDAQ, while DYN trades at $23.74.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ADPT currently has a P/E ratio of -42.44, whereas DYN's P/E ratio is -7.37. In terms of profitability, ADPT's ROE is -0.24%, compared to DYN's ROE of -0.58%. Regarding short-term risk, ADPT is less volatile compared to DYN. This indicates lower risk in terms of short-term price fluctuations for ADPT.Check DYN's competition here
Catalyst Pharmaceuticals, Inc. (NASDAQ: CPRX)
ADPT vs CPRX Comparison July 2026
Adaptive Biotechnologies Corporation (NASDAQ: ADPT) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ADPT stands at 3.7B. In comparison, CPRX has a market cap of 3.9B. Regarding current trading prices, ADPT is priced at $22.92 on the NASDAQ, while CPRX trades at $31.49.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ADPT currently has a P/E ratio of -42.44, whereas CPRX's P/E ratio is 12.30. In terms of profitability, ADPT's ROE is -0.24%, compared to CPRX's ROE of +0.24%. Regarding short-term risk, ADPT is more volatile compared to CPRX. This indicates higher risk in terms of short-term price fluctuations for ADPT.Check CPRX's competition here
NewAmsterdam Pharma Company N.V. (NASDAQ: NAMSW)
ADPT vs NAMSW Comparison July 2026
Adaptive Biotechnologies Corporation (NASDAQ: ADPT) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ADPT stands at 3.7B. In comparison, NAMSW has a market cap of 3.8B. Regarding current trading prices, ADPT is priced at $22.92 on the NASDAQ, while NAMSW trades at $20.56.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ADPT currently has a P/E ratio of -42.44, whereas NAMSW's P/E ratio is -11.36. In terms of profitability, ADPT's ROE is -0.24%, compared to NAMSW's ROE of -0.30%. Regarding short-term risk, ADPT is more volatile compared to NAMSW. This indicates higher risk in terms of short-term price fluctuations for ADPT.Check NAMSW's competition here
Enliven Therapeutics, Inc. (NASDAQ: ELVN)
ADPT vs ELVN Comparison July 2026
Adaptive Biotechnologies Corporation (NASDAQ: ADPT) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ADPT stands at 3.7B. In comparison, ELVN has a market cap of 3.8B. Regarding current trading prices, ADPT is priced at $22.92 on the NASDAQ, while ELVN trades at $53.20.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ADPT currently has a P/E ratio of -42.44, whereas ELVN's P/E ratio is -31.86. In terms of profitability, ADPT's ROE is -0.24%, compared to ELVN's ROE of -0.21%. Regarding short-term risk, ADPT is less volatile compared to ELVN. This indicates lower risk in terms of short-term price fluctuations for ADPT.Check ELVN's competition here
RayzeBio, Inc. Common Stock (NASDAQ: RYZB)
ADPT vs RYZB Comparison July 2026
Adaptive Biotechnologies Corporation (NASDAQ: ADPT) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ADPT stands at 3.7B. In comparison, RYZB has a market cap of 3.8B. Regarding current trading prices, ADPT is priced at $22.92 on the NASDAQ, while RYZB trades at $62.49.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ADPT currently has a P/E ratio of -42.44, whereas RYZB's P/E ratio is -57.86. In terms of profitability, ADPT's ROE is -0.24%, compared to RYZB's ROE of +0.83%. Regarding short-term risk, ADPT is more volatile compared to RYZB. This indicates higher risk in terms of short-term price fluctuations for ADPT.Check RYZB's competition here
CymaBay Therapeutics, Inc. (NASDAQ: CBAY)
ADPT vs CBAY Comparison July 2026
Adaptive Biotechnologies Corporation (NASDAQ: ADPT) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ADPT stands at 3.7B. In comparison, CBAY has a market cap of 3.7B. Regarding current trading prices, ADPT is priced at $22.92 on the NASDAQ, while CBAY trades at $32.48.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ADPT currently has a P/E ratio of -42.44, whereas CBAY's P/E ratio is -32.81. In terms of profitability, ADPT's ROE is -0.24%, compared to CBAY's ROE of -0.64%. Regarding short-term risk, ADPT is more volatile compared to CBAY. This indicates higher risk in terms of short-term price fluctuations for ADPT.Check CBAY's competition here
NewAmsterdam Pharma Company N.V. (NASDAQ: NAMS)
ADPT vs NAMS Comparison July 2026
Adaptive Biotechnologies Corporation (NASDAQ: ADPT) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ADPT stands at 3.7B. In comparison, NAMS has a market cap of 3.7B. Regarding current trading prices, ADPT is priced at $22.92 on the NASDAQ, while NAMS trades at $31.68.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ADPT currently has a P/E ratio of -42.44, whereas NAMS's P/E ratio is -19.92. In terms of profitability, ADPT's ROE is -0.24%, compared to NAMS's ROE of -0.30%. Regarding short-term risk, ADPT is more volatile compared to NAMS. This indicates higher risk in terms of short-term price fluctuations for ADPT.Check NAMS's competition here
Denali Therapeutics Inc. (NASDAQ: DNLI)
ADPT vs DNLI Comparison July 2026
Adaptive Biotechnologies Corporation (NASDAQ: ADPT) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ADPT stands at 3.7B. In comparison, DNLI has a market cap of 3.7B. Regarding current trading prices, ADPT is priced at $22.92 on the NASDAQ, while DNLI trades at $23.29.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ADPT currently has a P/E ratio of -42.44, whereas DNLI's P/E ratio is -8.09. In terms of profitability, ADPT's ROE is -0.24%, compared to DNLI's ROE of -0.52%. Regarding short-term risk, ADPT is more volatile compared to DNLI. This indicates higher risk in terms of short-term price fluctuations for ADPT.Check DNLI's competition here
Arcutis Biotherapeutics, Inc. (NASDAQ: ARQT)
ADPT vs ARQT Comparison July 2026
Adaptive Biotechnologies Corporation (NASDAQ: ADPT) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ADPT stands at 3.7B. In comparison, ARQT has a market cap of 3.6B. Regarding current trading prices, ADPT is priced at $22.92 on the NASDAQ, while ARQT trades at $28.49.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ADPT currently has a P/E ratio of -42.44, whereas ARQT's P/E ratio is -949.67. In terms of profitability, ADPT's ROE is -0.24%, compared to ARQT's ROE of -0.01%. Regarding short-term risk, ADPT is more volatile compared to ARQT. This indicates higher risk in terms of short-term price fluctuations for ADPT.Check ARQT's competition here
Tango Therapeutics, Inc. (NASDAQ: TNGX)
ADPT vs TNGX Comparison July 2026
Adaptive Biotechnologies Corporation (NASDAQ: ADPT) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ADPT stands at 3.7B. In comparison, TNGX has a market cap of 3.5B. Regarding current trading prices, ADPT is priced at $22.92 on the NASDAQ, while TNGX trades at $28.56.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ADPT currently has a P/E ratio of -42.44, whereas TNGX's P/E ratio is -34.33. In terms of profitability, ADPT's ROE is -0.24%, compared to TNGX's ROE of -0.42%. Regarding short-term risk, ADPT is less volatile compared to TNGX. This indicates lower risk in terms of short-term price fluctuations for ADPT.Check TNGX's competition here
Telix Pharmaceuticals Limited (NASDAQ: TLX)
ADPT vs TLX Comparison July 2026
Adaptive Biotechnologies Corporation (NASDAQ: ADPT) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ADPT stands at 3.7B. In comparison, TLX has a market cap of 3.5B. Regarding current trading prices, ADPT is priced at $22.92 on the NASDAQ, while TLX trades at $10.46.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ADPT currently has a P/E ratio of -42.44, whereas TLX's P/E ratio is -568.48. In terms of profitability, ADPT's ROE is -0.24%, compared to TLX's ROE of -0.02%. Regarding short-term risk, ADPT is more volatile compared to TLX. This indicates higher risk in terms of short-term price fluctuations for ADPT.Check TLX's competition here